Picture the harder half of a study visit. A participant with Parkinson's disease, somewhere between Hoehn and Yahr stages 2.5 and 4, has gone twelve hours without dopaminergic medication so that the motor examination can be scored in the OFF state. Then comes the levodopa dose, an hour's wait, and the same examination again in the ON state. Later, a magnetic coil is held over the scalp to read how excitable the motor cortex is, and blood goes off for cytokines and telomere length. That is the choreography described in a protocol paper published on January 9, 2026 in JMIR Research Protocols by Umesh Chikkanna and colleagues from the National Institute of Mental Health and Neurosciences (NIMHANS) in Bengaluru, working with the Central Council for Research in Ayurvedic Sciences (CCRAS). Its stated purpose is blunt: the trial "aims to address the lack of mechanistic evidence and robust data on Ayurveda in PD."
The design is a prospective, assessor-blinded, exploratory randomized controlled trial with parallel groups, 1:1 allocation and a superiority framing, run at that single tertiary centre over three years. Eighty people are to be randomized, forty per arm: one arm continues treatment as usual, the other receives a standardized Ayurvedic regimen alongside it for 180 days, delivered as three cycles at 60-day intervals. Each cycle opens with a short preparatory digestive phase (Deepana-Pachana, using a tablet formulation named in the protocol) and moves into a purification phase built around Yoga Basti, a prespecified sequence of decoction enemas (Niruha Basti) and oil enemas (Anuvasana Basti). Physiotherapy and occupational therapy are allowed and recorded as concomitant care; any Ayurvedic herbs or therapies outside the protocol are prohibited, precisely so the trial can say what it tested.
Who gets in matters as much as what they get. Eligibility runs from age 40 to 70, with idiopathic Parkinson's diagnosed by the UK Parkinson's Disease Society Brain Bank criteria, disease duration over three years, severe motor fluctuations and a suboptimal response to standard treatment, including dyskinesia and gait freezing, and a stable dopaminergic regimen for at least two weeks before baseline. People with parkinsonism spectrum or other neurodegenerative conditions are excluded. In other words, this is not a study of newly diagnosed, well-controlled disease. It is aimed squarely at the stage families know best: the stage where the medicines still work, but not evenly, and not all day.
The measurement layer is what makes this unusual for a complementary therapy. The primary outcome is the change in total MDS-UPDRS score after six months, with Part III scored in both ON and OFF states and interrater reliability checked in at least 20 percent of participants. Secondary and exploratory outcomes include single-pulse and paired-pulse transcranial magnetic stimulation measures (motor threshold, cortical silent period, short and long interval intracortical inhibition, intracortical facilitation), heart-rate variability for autonomic function, pulmonary function tests, shifts in Th1, Th2, Th17 and regulatory T cell populations with plasma pro-inflammatory cytokines, and telomere length at baseline and day 180. The authors are careful to call these hypotheses, not findings: they expect the regimen may modulate cortical excitability and immune markers, and they say so in the language of expectation. Liver and renal function tests run throughout for safety, a data and safety monitoring board constituted by CCRAS reviews adverse events, the NIMHANS ethics committee for research in AYUSH and integrative medicine approved the study on January 7, 2022, and the trial is registered with the Clinical Trial Registry of India as CTRI/2022/01/039803.
The honest reading of the paper is in its arithmetic. As of 2025, 259 people had been screened, 58 enrolled, 33 had completed the intervention and follow-up, 14 had discontinued and 11 were still in the study, with completion scheduled for September 2026: this month, on the paper's own timetable. The target of 80 was calculated from a prior exploratory study reporting a mean UPDRS change of 1.0 with a standard deviation of 2.0, which is a small base to build on, and the authors describe the sample as enough for preliminary insight and a basis for future confirmatory trials. There is no placebo and no sham: the comparator is usual care alone, so participants and the Ayurvedic clinicians know who is receiving what, and only the assessors are blinded. No interim efficacy analysis is planned. For a family reading this, the practical meaning is narrow but real: a therapy that usually reaches the literature as case reports is being tested with randomization, a registry entry, a monitoring board and a neurophysiology lab attached, and the answer, when it comes, will be checkable rather than anecdotal.
One more boundary deserves stating plainly, because it is the reason this sits in our pages. Cognition is tracked here as part of a broad neuropsychological battery, not as the trial's target, and Parkinson's disease dementia is not an outcome this study was built to answer. Anyone weighing an Ayurvedic add-on, including Basti therapy, is weighing a procedure that in this trial was delivered in a hospital, under screening, insurance cover and laboratory monitoring, and that conversation belongs with the neurologist who manages the levodopa.